VCFrance

The most common chronic disease in children, moderate to severe asthma remains imperfectly treated by current inhalation devices, leading to a high impact on school absenteeism and the quality of life of young patients. A population that has become a

VCFrance

The healthcare venture firm closes its fourth biotech fund, up 35%, and confirms a still-minority strategy in Europe: combining company creation and early-stage investments.Kurma Partners announces the final closing of Biofund IV at €215M, versus €16

VCFrance

Fueled by the rise of AI, BrainTech is asserting itself as one of the most promising segments of digital health. With a €60 million fund, Newfund intends to structure a market still largely dominated by the United States.USD 4.2 billion raised global

VCFrance

By closing its second fund, Jeito II, at more than one billion euros, Jeito Capital posts a record raise and brings its assets under management to €1.6 billion in five years.After a first vehicle raised at €534 million in 2021, Jeito Capital closes i

VCFrance

With a $320M fund launched in 2022, Pictet Alternative Advisors is deploying a private equity strategy entirely dedicated to health, from upstream innovation to care services, investing in the United States, Europe and Asia. The vehicle targets aroun

VCFrance

Innovation in health is no longer merely a scientific or economic issue: it has become a field of strategic confrontation. The United States, whichremain the leading financial and biotechnological power, are experiencing structural weakening, caught

VCEurope

It's a grand launch! Invest Europe and nine of the most active members in the healthtech sector of the European Economic Area, including Sofinnova Partners and Forbion, are inaugurating the European Life Sciences Coalition (ELSC) this week. The organ

Biotech

Less than six months after its creation, SATT Sayens has joined its capital. The biotech aims to become the "Moderna 2.0 of Crohn's disease and ulcerative colitis" with its first orally administered therapeutic RNAs.Oragen Therapeutics is off to a fl

Biotech

The Reims-based biotech, founded in 2019, is developing a peptide targeting the extracellular matrix, which activates immunity and prevents tumor vascularization. "For us, this is a key moment, allowing us to move from intention to clinical execut

Ecosystème

En 2025, pas moins de 46 autorisations de mise sur le marché (AMM) ont été effectuées par une FDA, pas épargnée par les tensions et l’agitation continue d’une administration emportée ou complice des lubies, des caprices, des engouements passagers e

Biotech

Iktos a conclu avec Servier le plus important contrat de son histoire, pouvant atteindre jusqu’à 1 milliard d’euros de paiements d’étapes. Dans la foulée, la techbio a annoncé un deal avec Pierre Fabre en oncologie… Le CEO Yann Gaston-Mathé nous écla

Biotech

Avec une trésorerie sécurisée jusqu’au premier semestre 2027, la biotech cotée monte en puissance dans la thérapie génique des surdités rares.Une levée majeure, un pipeline prometteur et Sanofi à bord : les catalyseursfinanciers sont là pour 2026 che